Equities research analysts expect Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) to post earnings per share of ($0.64) for the current quarter, Zacks reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.59). Iovance Biotherapeutics reported earnings per share of ($0.51) in the same quarter last year, which suggests a negative year-over-year growth rate of 25.5%. The company is expected to announce its next quarterly earnings report after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.23). For the next year, analysts forecast that the business will report earnings of ($2.35) per share, with EPS estimates ranging from ($2.81) to ($1.92). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). During the same quarter in the prior year, the firm earned ($0.47) EPS.
Hedge funds have recently made changes to their positions in the company. UBS Group AG grew its stake in shares of Iovance Biotherapeutics by 213.8% in the third quarter. UBS Group AG now owns 196,284 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 133,742 shares during the period. Principal Financial Group Inc. grew its stake in shares of Iovance Biotherapeutics by 4.1% in the third quarter. Principal Financial Group Inc. now owns 546,867 shares of the biotechnology company’s stock worth $13,486,000 after acquiring an additional 21,784 shares during the period. Banque Pictet & Cie SA grew its stake in shares of Iovance Biotherapeutics by 701.0% in the fourth quarter. Banque Pictet & Cie SA now owns 534,036 shares of the biotechnology company’s stock worth $10,195,000 after acquiring an additional 467,364 shares during the period. Senator Investment Group LP bought a new stake in shares of Iovance Biotherapeutics in the third quarter worth approximately $12,330,000. Finally, Boxer Capital LLC bought a new stake in shares of Iovance Biotherapeutics in the third quarter worth approximately $27,126,000. Hedge funds and other institutional investors own 94.37% of the company’s stock.
Shares of NASDAQ IOVA opened at $15.15 on Thursday. Iovance Biotherapeutics has a 1 year low of $12.18 and a 1 year high of $32.15. The stock has a market cap of $2.38 billion, a P/E ratio of -6.82 and a beta of 0.83. The firm has a 50-day moving average of $15.72 and a 200 day moving average of $17.94.
Iovance Biotherapeutics Company Profile (Get Rating)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.